RNA vs FOLD vs RARE vs SRPT

For growth investors, Atrium Therapeutics, Inc.

(RNA) is the stronger pick with 70. 9% revenue growth year-over-year, versus 15. 6% for Sarepta Therapeutics, Inc. (SRPT). Analysts rate Amicus Therapeutics, Inc. (FOLD) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Amicus Therapeutics, Inc.

(FOLD) delivered a total return of +40. 0%, compared to -81. 0% for Sarepta Therapeutics, Inc. (SRPT). Over 10 years, the gap is even starker: FOLD returned +137. 5% versus RARE's -59. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Amicus Therapeutics, Inc.

(FOLD) is the lower-risk stock at 0. 48β versus Sarepta Therapeutics, Inc. 's 2. 10β — meaning SRPT is approximately 335% more volatile than FOLD relative to the S&P 500. On balance sheet safety, Atrium Therapeutics, Inc. (RNA) carries a lower debt/equity ratio of 2% versus 176% for Amicus Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Atrium Therapeutics, Inc.

(RNA) is pulling ahead at 70. 9% versus 15. 6% for Sarepta Therapeutics, Inc. (SRPT). On earnings-per-share growth, the picture is similar: Amicus Therapeutics, Inc. grew EPS 51. 2% year-over-year, compared to -404. 7% for Sarepta Therapeutics, Inc.. Over a 3-year CAGR, SRPT leads at 33. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Amicus Therapeutics, Inc.

(FOLD) is the more profitable company, earning -4. 3% net margin versus -411. 9% for Atrium Therapeutics, Inc. — meaning it keeps -4. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: FOLD leads at 5. 4% versus -412. 6% for RNA. At the gross margin level — before operating expenses — RNA leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Sarepta Therapeutics, Inc.

(SRPT) trades at 4. 5x forward P/E versus 40. 6x for Amicus Therapeutics, Inc. — 36. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RNA: 96. 1% to $25. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Amicus Therapeutics, Inc.

(FOLD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 48), +137. 5% 10Y return). Sarepta Therapeutics, Inc. (SRPT) carries a higher beta of 2. 10 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (FOLD: +137. 5%, SRPT: -16. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.